EWING, N.J.--(BUSINESS WIRE)--Antares Pharma, Inc. (AMEX: AIS) announced that the Company has received an additional milestone payment of $875,000 from BioSante Pharmaceuticals Inc. (NASDAQ: BPAX) pursuant to a marketing agreement with Bradley Pharmaceuticals, Inc. (NYSE: BDY) for Elestrin™, a low dose transdermal estradiol therapy delivered in our proprietary Advanced Transdermal Delivery (ATD™) gel system. Elestrin is used for the treatment of hot flashes in menopausal women. Additional sales based milestone payments could bring the total payments to Antares to more than $13 million. Antares also receives an important portion of the royalties on third party sales.
